OrbusNeich Medical Group

Simplify the Complex in Coronary Lesion Management

OrbusNeich won the ‘Outstanding Innovative Medical Device Solution’ at the Health Partnership Awards 2025.

The TricValve system treats tricuspid insufficiency with two self-expanding biological valves implanted percutaneously.

The page features physician interviews and expert insights on OrbusNeich’s interventional solutions.

Explore OrbusNeich Academy, the central hub for clinical learning with expert insights, educational resources, clinical papers, and product knowledge.

Discover OrbusNeich event highlights through articles and videos, featuring conference updates, clinical insights, and key moments from global events.

The U.S. Food and Drug Administration approved OrbusNeich’s Scoreflex NC Scoring PTCA Catheter for coronary artery use.

OrbusNeich’s device portfolio supports lesion management during coronary and peripheral procedures.

The page provides information on OrbusNeich’s history, board, management, and global locations.

OrbusNeich has earned numerous accolades for product and service excellence, as well as for its community contributions over the years.

The page outlines OrbusNeich’s Code of Business Conduct and Ethics.

OrbusNeich is a leading global medical device company specializing in PCI and PTA interventional devices. Access the corporate factsheet, company profile, and key milestones here.

OrbusNeich offers product information upon request.

OrbusNeich develops devices like balloons, stents, and catheters for vascular disease treatment.

OrbusNeich’s product information is intended for medical professionals and does not provide medical advice.

OrbusNeich Medical Group Holdings Limited appoints **Kwai Ching Denise Lau** as **Co-Chief Executive Officer**, effective August 17, 2026. Lau, previously serving as **Chief Operating Officer** since 2020 and an **Executive Director** since 2021, joins alongside **David Chien**. The company had previously named her an Executive Director in 2021 after her tenure as a non-executive director since 2021.

Aug 2026MarketScreenerNews article

OrbusNeich becomes the sole recipient of awards at both the **Asia Pacific Enterprise Awards (APEA)** and the **AREA 2026 China Chapter** for its contributions to healthcare innovation. The company’s advancements in medical technology and solutions are recognized for driving progress in the industry. This dual recognition highlights its leadership in developing cutting-edge healthcare products.

Aug 2026Dailywire.asia: Global News & Insights for AsiaNews article

Orbus Neich Medical Group Holdings Limited enrolls the first patient in its pivotal **OM-0031** clinical trial in Japan, evaluating its proprietary **paclitaxel drug-coated balloon (DCB)** for coronary applications. The trial represents a key milestone in advancing the company’s cardiovascular device portfolio. Shareholders and investors receive the update as part of the company’s voluntary disclosures.

Jul 2026MarketScreenerNews article

OrbusNeich Medical Group Holdings Limited releases its financial results for the full year ended December 31, 2025. The company provides medical devices and technologies, including coronary and peripheral vascular solutions. Key metrics and performance highlights are included in the earnings report.

Mar 2026MarketScreenerNews article